Leerink Swann Comments on Eli Lilly and Company’s FY2018 Earnings (NYSE:LLY)
Eli Lilly and Company (NYSE:LLY) – Equities researchers at Leerink Swann lifted their FY2018 earnings per share estimates for shares of Eli Lilly and Company in a report released on Monday. Leerink Swann analyst S. Fernandez now forecasts that the company will post earnings of $4.37 per share for the year, up from their previous forecast of $4.30. Leerink Swann currently has a “Outperform” rating on the stock.
Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, April 25th. The company reported $0.98 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.96 by $0.02. The firm had revenue of $5.23 billion during the quarter, compared to analyst estimates of $5.22 billion. Eli Lilly and Company had a return on equity of 26.64% and a net margin of 10.13%. Eli Lilly and Company’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.83 earnings per share.
WARNING: This article was originally published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/07/11/leerink-swann-comments-on-eli-lilly-and-companys-fy2018-earnings-nyselly.html.
A number of other research analysts have also commented on the stock. Zacks Investment Research raised shares of Eli Lilly and Company from a “sell” rating to a “hold” rating in a research report on Tuesday. Citigroup Inc. reissued a “buy” rating and issued a $100.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, July 4th. Barclays PLC increased their price target on shares of Eli Lilly and Company from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 4th. Jefferies Group LLC reissued a “buy” rating and issued a $93.00 price target on shares of Eli Lilly and Company in a research report on Thursday, June 22nd. Finally, BidaskClub raised shares of Eli Lilly and Company from a “sell” rating to a “hold” rating in a research report on Wednesday, June 14th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and eleven have given a buy rating to the company. Eli Lilly and Company currently has an average rating of “Hold” and an average price target of $87.65.
Shares of Eli Lilly and Company (NYSE LLY) traded down 0.19% during mid-day trading on Tuesday, reaching $82.12. The company had a trading volume of 1,630,122 shares. The company’s 50-day moving average price is $80.49 and its 200-day moving average price is $79.95. The company has a market capitalization of $86.74 billion, a PE ratio of 39.71 and a beta of 0.35. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72.
Hedge funds have recently added to or reduced their stakes in the stock. First Command Financial Services Inc. boosted its stake in Eli Lilly and Company by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock valued at $103,000 after buying an additional 84 shares during the period. Heritage Trust Co bought a new stake in Eli Lilly and Company during the first quarter valued at approximately $135,000. Point72 Asia Hong Kong Ltd boosted its stake in Eli Lilly and Company by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after buying an additional 1,239 shares during the period. LeJeune Puetz Investment Counsel LLC bought a new stake in Eli Lilly and Company during the fourth quarter valued at approximately $136,000. Finally, Penserra Capital Management LLC boosted its stake in Eli Lilly and Company by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after buying an additional 176 shares during the period. 75.41% of the stock is currently owned by institutional investors and hedge funds.
In other news, major shareholder Lilly Endowment Inc sold 215,000 shares of the stock in a transaction that occurred on Tuesday, June 20th. The shares were sold at an average price of $83.05, for a total transaction of $17,855,750.00. Following the sale, the insider now directly owns 124,475,804 shares of the company’s stock, valued at $10,337,715,522.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Melissa S. Barnes sold 1,900 shares of the stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $80.78, for a total transaction of $153,482.00. Following the sale, the insider now directly owns 14,041 shares in the company, valued at $1,134,231.98. The disclosure for this sale can be found here. Insiders have sold 474,733 shares of company stock worth $39,634,487 over the last ninety days. Insiders own 0.20% of the company’s stock.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be paid a dividend of $0.52 per share. The ex-dividend date is Friday, August 11th. This represents a $2.08 annualized dividend and a yield of 2.53%. Eli Lilly and Company’s dividend payout ratio is 100.48%.
Eli Lilly and Company Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.